Cardinal Health, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cardinal Health, Inc.
European Probiotics specialist Probi has acquired a stake in US supplements firm Vital Nutrients, in a deal which will see the companies collaborate on new product development.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Cancer deals involve City of Hope/Chimeric, CARISMA/NYU, Sorrento/Mayo Clinic, Rain/Drexel, Diaprost/Memorial Sloan Kettering, Alkido/University of Kentucky. Plus, research collaborations in brief.
Probi's probiotic "significantly decreased" plasma levels of two inflammatory markers coupled to acute stress in study, with the firm planning further research into the gut-brain axis.
- Contract Research, Toxicology Testing-CRO
- Medical Devices
- Home Infusion
- Hospitals, Nursing Homes, Institutions
- Pharmacy Services, PBMs
- Controlled Release
- Drug Delivery
- Other Names / Subsidiaries
- Allegiance Healthcare Corporation
- Cordis Corporation
- Innovative Therapies, naviHealth
- The Harvard Drug Group
- VIASYS Healthcare